Abstract:e17561 Background: to evaluate the activity and mechanism of rAd-p53 combined with chemotherapeutics in treatment of ATC in vitro and in vivoand clinical therapies. Methods: p53-mutant ATC cells (C643 cells) were received with vehicle, paclitaxel, cisplatin, rAd-p53, paclitaxel combined with cisplatin, and rAd-p53 combined with paclitaxel and cisplatin to evaluate the in vitro anti-tumor activity and mechanism. The in vivo anti-tumor activity of rAd-p53 combined with paclitaxel and cisplatin was evaluated with a C643 xenograft model. Intratumoral rAd-p53 was administered at a dose of 1×1010 VP/cm2 per 3 days for 8 times and intraperitoneal injection of Paclitaxel and cisplatin was administered at a dose of 5 mg/kg per 5 days for 4 times. The ATC patients received a pre-operative rAd-p53 therapy combined with chemotherapeutic treatment. rAd-p53 was injected intra-tumoral with 2-4×1012rAd-p53 viral particles (VP) per 3 days for 10 times. A cycle of chemotherapy including paclitaxel and cisplatin were also finished. Results: Both of MTT assay and C643 xenograft modelshowed rAd-P53 combined with paclitaxel and cisplatin significantly inhibited the growth of C643 tumors. And rAd-P53 displayed an enhanced sensitivity to chemotherapeutics. The in vitroexperiments demonstrated that rAd-P53 combined with paclitaxel and cisplatin did not only induce C643 cells apoptosis with DNA damage pathway but also inhibit cell metastasis via Raf-MEK-Erk pathway. 2 ATC patients who received rAd-p53 intratumoral injection and chemotherapy had a continued response (CR) and without evidence of distant metastasis after the combined treatment, then received surgery. All cases were followed up and the survival time for ATC patients was between 9-35 months. Conclusions: rAd-P53 combined with paclitaxel and cisplatin showed an enhanced sensitivity to chemotherapeutics to inhibit the tumor growth of C643 cells both in in vitro and in vivo. ATC patients receiving a pre-operative rAd-p53 therapy combined with chemotherapeutic treatment had a radical surgery and long-term survival. These results hinted that rAd-P53 combined with chemotherapeutics had a potential utility for the clinical treatment for ATC.

P53-Dependent Apoptosis is Essential for the Antitumor Effect of Paclitaxel Response to DNA Damage in Papillary Thyroid Carcinoma.

Recombinant Human Adenovirus P53 Injection Enhanced Sensitivity Of Chemotherapeutics Through Dna Damage Response Pathway In Advanced Papillary Thyroid Cancer In Vitro And In Vivo

Paclitaxel Induce Apoptosis of Giant Cells Tumor of Bone Via TP53INP1 Signaling

Recombinant Human Adenovirus P53 Injection (Rad-P53) is A Challenge for Anaplastic Thyroid Cancer Treatment

Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.

Pifithrin-α Enhancing Anticancer Effect of Topotecan on P53-Expressing Cancer Cells

Concentration-dependent Differential Effects of an Epothilone Analog on Cell Cycle and P53 Signaling.

Reduced Expression of P53 and P21(Waf1/Cip1) Sensitizes Human Breast Cancer Cells to Paclitaxel and Its Combination with 5-Fluorouracil

Apoptosis Induced By Low-Dose Paclitaxel Is Associated With P53 Upregulation In Nasopharyngeal Carcinoma Cells

Preoperative Recombinant Adenoviral Human P53 Gene Combined with Intensity-Modulated Radiation Therapy in Treatment of Stage IV Papillary Thyroid Carcinoma: A Randomized Clinical Study.

Expression of PUMA in Papillary Thyroid Carcinoma and Its Role in Inducing Apoptosis

Restoration of P53 Using the Novel MDM2-p53 Antagonist APG115 Suppresses Dedifferentiated Papillary Thyroid Cancer Cells

Triptolide Induces Apoptosis in Human Anaplastic Thyroid Carcinoma Cells by A P53-Independent but Nf-Kappa B-Related Mechanism

P-Glycoprotein-Independent Apoptosis Induction By A Novel Synthetic Compound, Mmpt [5-[(4-Methylphenyl)Methylene]-2-(Phenylamino)-4 (5h)-Thiazolone]

Attenuation of aggressive tumor progression of anaplastic thyroid cancer by p53

Inhibition of Nuclear Factor-Κb by an Antioxidant Enhances Paclitaxel Sensitivity in Ovarian Carcinoma Cell Line

Paclitaxel mediates the PI3K/AKT/mTOR pathway to reduce proliferation of FLT3‐ITD + AML cells and promote apoptosis

Natural Phycocyanin/Paclitaxel Micelle Delivery of Therapeutic P53 to Activate Apoptosis for HER2 or ER Positive Breast Cancer Therapy

The inhibition of Beclin1-dependent autophagy sensitizes PTC cells to ABT737-induced death

Paclitaxel Inhibits Thyroid Cancer by Regulating AMPK/mTOR and Promoting Ferroptosis

Activation of the Mitochondria-Driven Pathway of Apoptosis in Human PC-3 Prostate Cancer Cells by a Novel Hydrophilic Paclitaxel Derivative, 7-Xylosyl-10-deacetylpaclitaxel.